


# MECHANISM OF ACTION OF RIVOCERANIB IN SOLID TUMORS



Scan to learn more



Rivoceranib is an oral tyrosine kinase inhibitor (TKI) that potently and selectively inhibits VEGFR<sup>1,2</sup>

With the increased selectivity seen with rivoceranib, more effective targeting of VEGFR may be achieved.